抗ALK2重组抗体促进组织铁再分布并改善炎症性贫血小鼠模型的贫血
该研究表征了针对BMP受体ALK2的研究性抗体RKER-216,探讨其抑制铁调素、改善急慢性炎症贫血的机制。RKER-216通过竞争性阻断BMP6结合中和ALK2活性,降低Hep3B细胞铁调素转录;野生型小鼠皮下3 mg/kg可抑制血清铁调素并升高循环铁3-4天;在脂多糖炎症和腺嘌呤诱导CKD贫血小鼠中降低铁调素、释放回收途径铁并改善贫血;与rhEPO联用可完全纠正贫血。
要点
- RKER-216通过竞争性阻断BMP6结合中和ALK2,降低Hep3B细胞铁调素转录。
- 野生型小鼠皮下注射3 mg/kg RKER-216可抑制血清铁调素并升高循环铁3-4天。
- RKER-216与rhEPO联用可满足CKD贫血小鼠完全纠正贫血的铁需求。
核心结论
- 数据支持ALK2是关键的铁调素调节因子,中和性ALK2抗体有潜力作为单药或与rhEPO联用恢复铁稳态以改善炎症性贫血。
研究设计与样本
- 研究性抗体RKER-216的体外细胞实验与野生型小鼠、脂多糖介导炎症小鼠及腺嘌呤诱导慢性肾脏病贫血小鼠模型研究。
主要发现
- RKER-216通过竞争性阻断BMP6结合中和ALK2活性,并降低Hep3B细胞铁调素转录。
- 野生型小鼠皮下单次3 mg/kg RKER-216抑制血清铁调素并升高循环铁持续3-4天。
- RKER-216通过抑制SMAD1/5/9信号降低脂多糖介导炎症小鼠的铁调素。
- RKER-216释放回收途径铁以改善腺嘌呤诱导慢性肾脏病贫血小鼠的贫血。
- RKER-216逆转CKD小鼠的铁限制性红细胞生成,与rhEPO联用可满足完全纠正贫血的铁需求。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic inflammation are burdened with anemia of inflammation (AI), where inflammatory cytokines inhibit erythropoiesis, impede erythropoietin production, and limit iron availability by inducing the iron regulator hepcidin. High hepcidin hinders iron absorption and recycling, thereby worsening the impaired erythropoiesis by restricting iron availability. AI management is important as anemia impacts quality of life and potentially affects morbidity and mortality. The bone morphogenetic protein (BMP)-SMAD pathway is crucial for hepcidin regulation. Here, we characterized a research antibody against BMP receptor ALK2, RKER-216, and investigated its mechanism in suppressing hepcidin and improving anemia in acute/chronic inflammation. Additive effects of RKER-216 and recombinant human erythropoietin (rhEPO) on erythropoiesis and iron utilization were also explored. We showed that RKER-216 neutralized ALK2 activity by competing with the binding of BMP6. RKER-216 reduced hepcidin transcription in Hep3B cells, and a subcutaneous dose of RKER-216 at 3 mg/kg suppressed serum hepcidin and increased circulating iron for 3-4 days in wildtype mice. Moreover, RKER-216 decreased hepcidin by inhibiting SMAD1/5/9 signaling in lipopolysaccharide-mediated inflammation and liberated iron from the recycling pathway to alleviate anemia in mice with adenine-induced chronic kidney disease (CKD), a mouse model of AI. Finally, RKER-216 reversed iron-restricted erythropoiesis in CKD mice and supplied the iron requirement for complete resolution of anemia when coupled with rhEPO in addressing AI. Our data support that ALK2 is a key hepcidin regulator and that a neutralizing ALK2 antibody has the potential to restore iron homeostasis as monotherapy or in combination with rhEPO to ameliorate AI.
引用
- Wang CY, Melgar-Bermudez E, Welch D, et al. A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation. Am J Hematol. 2025. PMID: 39791515. doi:10.1002/ajh.27578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。